New Zealand Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

New Zealand Pharmaceuticals and Healthcare Report Q3 2013 May 22nd 2013, 00:00 BMI View: Low growth potential in New Zealand’s pharmaceutical market will attract risk-averse investors. However, we note that regulatory delays in funding new medicines will hinder patients’ access to pharmaceuticals, constituting a downside risk for drug companies looking to sell their products in the country. Headline Expenditure Forecasts ? Pharmaceuticals: NZD1.36bn (US$1.10bn) in 2012 to NZD1.37bn (US$1.06bn) in 2013; +0.5% in local currency and -3.8% in US dollar terms. ? Healthcare: NZD21.22bn (US$17.19bn) in 2012 to NZD21.96bn (US$17.02bn) in 2013; +3.5% in local currency and -1.0% in US dollar terms. Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=97332. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/new-zealand-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions